Alector (ALEC) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pyxis Oncology (PYXS) has outperformed Alector (ALEC) over the past year, losing 31.6% versus a loss of 34.4%. Over five years, PYXS leads with a -83.1% price change compared with -91.3% for ALEC. Pyxis Oncology is the larger company by market cap ($239.5 million vs $233.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | PYXS |
|---|---|---|
| Share price | $2.09 | $2.01 |
| Market cap | $233.46M | $239.51M |
| 1-day change | +3.51% | +0.75% |
| YTD return | +29.49% | +73.04% |
| 1-year return | -34.42% | -31.62% |
| 5-year return | -91.33% | -83.09% |
| EPS (TTM) | $-1.09 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.40 | $5.55 |
| 52-week low | $1.09 | $1.03 |
| Distance from 52-week high | -38.50% | -63.87% |
| Analyst consensus | hold | none |
| Avg. price target upside | +57.83% | +332.42% |
| Average volume | 2.86M | 1.26M |
| Shares outstanding | 111.66M | 119.46M |
| Employees | 103 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
ALEC vs PYXS FAQ
Which is bigger, Alector or Pyxis Oncology?
Pyxis Oncology (PYXS) is larger, with a market capitalization of $239.51M compared with $233.46M for Alector (ALEC).
Which stock has performed better over the past year, ALEC or PYXS?
PYXS returned -31.62% over the past 12 months, compared with -34.42% for ALEC (price return, excluding dividends). Past performance does not predict future results.
Are Alector and Pyxis Oncology in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Alector and Biotechnology: Pharmaceutical Preparations for Pyxis Oncology.